<?xml version='1.0' encoding='utf-8'?>
<document id="23970584"><sentence text="Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety." /><sentence text="This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient" /><sentence text=" A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia"><entity charOffset="69-82" id="DDI-PubMed.23970584.s3.e0" text="triamcinolone" /></sentence><sentence text=" Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy"><entity charOffset="115-128" id="DDI-PubMed.23970584.s4.e0" text="triamcinolone" /></sentence><sentence text=" The patient's antiretroviral regimen was thus changed to replace her protease inhibitor with the integrase inhibitor raltegravir"><entity charOffset="118-129" id="DDI-PubMed.23970584.s5.e0" text="raltegravir" /></sentence><sentence text=" Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome" /><sentence text=" First described in 1996, this hypersensitivity syndrome presents with severe skin reaction as well as fever, rash, lymphadenopathy and internal organ involvement with marked eosinophilia" /><sentence text=" Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy"><entity charOffset="31-42" id="DDI-PubMed.23970584.s8.e0" text="raltegravir" /></sentence><sentence text="" /></document>